Mr Robert B. Bell > Hughes Hubbard & Reed LLP > Washington DC, United States > Lawyer Profile

Hughes Hubbard & Reed LLP
WASHINGTON, DC 20006-2401
United States


Robert B. Bell is a partner in the Washington, DC, office of Hughes Hubbard & Reed. He is a former clerk to US Supreme Court Justice Byron R. White and US District Court Judge Thomas A. Flannery. Robert has wide experience securing antitrust clearance for mergers and acquisitions from both the Department of Justice and the Federal Trade Commission, and in representing companies and individuals in criminal and civil antitrust matters. He also regularly counsels clients on matters involving antitrust litigation and provides antitrust counseling on issues ranging from competitor collaborations to vertical distribution arrangements. His experience covers a wide array of industry sectors, including imaging, communications, defense, entertainment, manufacturing, mining, chemicals and transportation.


Stanford Law School, J.D., 1980, Order of the Coif., Editor, Stanford Journal of International Studies
University of Cambridge, M.A., Economics, 1977
Dartmouth College, B.A., 1975, Phi Beta Kappa, summa cum laude

Lawyer Rankings

United States > Antitrust > Merger control

Hughes Hubbard & Reed LLP handles the full range of merger-related issues, including clearance filings, regulatory reviews and investigations, and representing clients against DOJ and FTC challenges. The firm has strong international expertise, including knowledge of antitrust regulations in China and Europe, and also offers a strong specialism to clients in the pharmaceutical, electronics, media & entertainment, and financial services industries. The Washington DC-based team is led by William J. Kolasky, a former deputy assistant Attorney General at the DOJ Antitrust Division, who has a successful record in merger clearances. Robert B. Bell is another key name, and combines merger control advice with regular work in government investigations. Philip Giordano continues to be active, and is currently representing ANI Pharmaceuticals in its high-profile pending acquisition of Novitium Pharma.